查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1656918

高通量篩檢的全球市場:洞察，競爭情形，市場預測:2032年

High-Throughput Screening - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

預計高通量篩選 (HTS) 市場規模在預測期內（即 2025-2032 年）將以 10.61% 的複合年增長率擴大。由於慢性病和傳染病患者病率不斷上升、研究合作不斷擴大以及主要參與者的產品開發，全球高通量篩檢市場預計將快速成長。藥物研發技術的不斷進步和精準醫療需求的不斷增長是推動市場擴張的主要因素之一。此外，增加資金以加速藥物發現也是預測期（即 2025-2032 年）內高通量篩選市場實現正成長的主要因素。

根據美國疾病管制與預防中心（CDC）2024年2月發布的數據，到2024年，美國預計將有1.29億人患有至少一種重大慢性病，如心臟病、癌症、糖尿病、肥胖症或高血壓。癌症是影響全世界人民的主要慢性疾病。根據國際癌症研究機構2020年12月的調查顯示，預計2020年全球通報新發癌症病例1,930萬例。

根據世界衛生組織（WHO）2022年的數據，2020年全球報告的乳癌約226萬例，肺癌約221萬例，大腸癌約193萬例，攝護腺癌約141萬例，胃癌約109萬例。 HTS 有可能發現針對多種癌症類型的創新標靶療法、化療方案和免疫系統調節劑。它還可以幫助確定協同藥物組合併制定針對每個腫瘤特定分子特徵的個人化治療計劃。

HTS 檢測可以透過針對涉及病原體複製、毒力和宿主細胞相互作用的關鍵微生物酶和途徑來識別潛在的藥物標靶和先導化合物。根據世界衛生組織（WHO）2022年的數據，估計全球約有3.54億人感染B型肝炎或C型肝炎。因此，傳染病病例的增加將進一步增加對診斷的需求，從而促進市場成長。

HTS 檢測和儀器的廣泛使用以及主要公司之間研究合作的不斷增加正在推動市場的成長。這些公司開發創新的智慧檢測並提供早期藥物發現來識別新的藥物標靶和細胞途徑。例如，2023 年 5 月，Axxam SpA 宣布已與 Promega Corporation 進行研發合作，開發尖端的無細胞和基於細胞的發光檢測方法，這些檢測方法小型化並專門針對全自動高通量篩選 (HTS) 設定。

由於藥物發現過程的快速變化，技術進步在高通量篩選中發揮著至關重要的作用。人工智慧（AI）正在徹底改變藥物發現中的高通量篩選（HTS），顯著提高其在藥物開發早期階段的效率、準確性和預測能力。這些市場發展正在推動對高通量篩選的需求，預計這將在預測期內推動市場成長。

本報告提供全球高通量篩檢市場相關調查，提供市場概要，以及各產品，各技術，各用途，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 高通量篩檢市場報告的簡介

第2章 高通量篩檢市場摘要整理

第3章 競爭情形

第4章 法規分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第5章 高通量篩檢市場主要原因分析

  • 高通量篩檢市場促進因素
  • 高通量篩檢市場阻礙因素與課題
  • 高通量篩檢市場機會

第6章 高通量篩檢市場上波特的五力分析

第7章 高通量篩檢市場評估

  • 各產品
    • 設備
    • 試劑和套件
    • 軟體
  • 各技術
    • 細胞為基礎的化驗
    • 超高通量篩檢
    • 實驗室晶片技術
    • 免標定高通量篩檢
    • 次世代定序(NGS)
  • 各用途
    • 體外ADME分析
    • 醫藥品的發現與開發
    • 治療藥監測
    • 先導藥物最適化
    • 其他
  • 各終端用戶
    • 製藥公司·生物科技企業
    • CRO
    • 學術機構及政府機關
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 高通量篩檢市場企業與產品簡介

  • Agilent Technologies, Inc.
  • Axxam S.p.A.
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Merck & Co., Inc.
  • PerkinElmer Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • Promega Corporation
  • Aurora Biomed Inc.
  • Illumina, Inc.
  • Oxford Nanopore Technologies plc
  • Corning Incorporated
  • F. Hoffmann-La Roche Ltd
  • Sygnature Discovery
  • BPS Bioscience, Inc.
  • Revvity
  • Charles River Laboratories
  • Hamilton Company
  • UPM Biomedicals

第9章 KOL的見解

第10章 計劃的方法

第11章 關於DelveInsight

第12章 免責聲明和諮詢方式

Product Code: DIMDCL0857

High-Throughput Screening Market by Product (Instruments, Reagents and Kits, and Software), Technology (Cell-Based Assays, Ultra-High-Throughput Screening, Lab-On-A-Chip Technology, Label-Free High-Throughput Screening, and Next-Generation Sequencing (NGS), Application (In Vitro ADME Analysis, Drug Discovery & Development, Therapeutic Drug Monitoring, Lead Optimization, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product development by key players

The high-throughput screening market is estimated to grow at a CAGR of 10.61% during the forecast period from 2025 to 2032. The global high-throughput screening market is expected to grow a rapid pace due to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product developments by key players. Increasing technological advancements in drug discovery and the growing demand of precision medicine are some of the key factors contributing to propel the market expansion. Additionally, the increasing funding to accelerate drug discovery is also a key factor responsible for contributing to the positive growth of the high-throughput screening market during the forecast period from 2025 to 2032.

High-Throughput Screening Market Dynamics:

According to the data provided by the Centers for Disease Control and Prevention (CDC) published in February 2024, an estimated 129 million people were suffering from at least 1 major chronic disease such as heart disease, cancer, diabetes, obesity, and hypertension in the United States as of 2024. Cancer is a major chronic disease affecting people around the world. As per the study conducted by the International Agency for Research on Cancer in December 2020, mentioned, an estimated 19.3 million new cancer cases were reported in 2020 across the globe.

According to data cited by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 globally. HTS has the potential to uncover innovative targeted treatments, chemotherapy options, or immune system-regulating medications for various cancer types. Additionally, it aids in pinpointing combinations of drugs that work together synergistically, as well as crafting personalized treatment plans tailored to the unique molecular characteristics of individual tumors.

The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the high-throughput screening (HTS) market, as HTS assays can target essential microbial enzymes or pathways involved in pathogen replication, virulence, or host-cell interactions to identify potential drug targets and lead compounds. According to the World Health Organization (WHO) in 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally. Therefore, the increasing number of cases of infectious diseases will further increase the demand for diagnosis, thus contributing to market growth.

The rising research collaborations among key players are bolstering market growth due to the extensive use of HTS assays and instruments. These players are developing innovative smart assays to offer early-stage drug discovery to identify novel drug targets and cellular pathways. For instance, in May 2023, Axxam S.p.A., announced that it entered into a research collaboration with Promega Corporation, to develop cutting-edge luminescence-based assays, both cell-free and cell-based, tailored for miniaturized and fully automated high-throughput screening (HTS) setups.

In September 2023, SCIEX, a US-based mass spectrometry and capillary electrophoresis solutions entered into a research partnership with HighRes Biosolutions for precision detection and quantification of molecules in drug discovery.

In September 2022, Illumina, Inc., a US-based biotechnology company launched NovaSeq X and NovaSeq X Plus developed for genomic drug discovery. The NovaSeq X Plus has the capacity to produce over 20,000 whole genomes annually, which is 2.5 times faster than previous sequencers. This significant increase in throughput speeds up genomic exploration and medical understanding, leading to advancements in disease comprehension and potentially revolutionizing patient care.

Technological advancements play a pivotal role in high-throughput screening due to rapid transformation in the drug discovery process. Artificial Intelligence (AI) has revolutionized high throughput screening (HTS) in drug discovery, markedly enhancing efficiency, precision, and predictive capacities during the initial phases of drug development. Such developments in the market drive the demand for high-throughput screening, which promises a positive growth outlook for the market during the forecast period.

However, the high cost associated with the instrumentation and drug discovery process, and complexities in the assay development process, among others are some of the key constraints that may limit the growth of the high-throughput screening market.

High-Throughput Screening Market Segment Analysis:

High-Throughput Screening Market by Product (Instruments, Reagents and Kits, and Software), Technology (Cell-Based Assays, Ultra-High-Throughput Screening, Lab-On-A-Chip Technology, Label-Free High-Throughput Screening, and Next-Generation Sequencing (NGS), Application (In Vitro ADME Analysis, Drug Discovery & Development, Therapeutic Drug Monitoring, Lead Optimization, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment, the cell-based assay category was estimated to generate the largest revenue share in the high-throughput screening market in 2024. This can be attributed to cell-based assays, which constitute over half of all high-throughput drug screenings, serving purposes such as target validation and assessing ADMET (absorption, distribution, metabolism, elimination, and toxicity) in the initial phases of drug discovery. Key players in the market are developing innovative screening workflow automation to develop effective cellular assays to enhance drug discovery. For instance, in February 2023, Agilent Technologies Inc., a US-based pharmaceutical and medical technology company launched the xCELLigence RTCA HT (real-time cell analysis high-throughput) platform seamlessly integrates with the BioTek BioSpa 8 Automated Incubator. The xCELLigence RTCA HT technology has played a pivotal role in enabling high-throughput, swift, and quantitative monitoring of cytopathic effect (CPE), serving as a valuable tool for evaluating neutralizing activity and potency.

In January 2024, BD, a US-based pharmaceutical and medical technology company announced its collaboration with Hamilton, a laboratory automation technology company to develop robotics-compatible reagent kits to facilitate greater standardization and minimize human error during large-scale single-cell multiomics experiments to reduce potential biases.

Further, cell-based assays are versatile tools utilized in biomedical research and drug discovery screening. They effectively measure cytotoxicity, biological activity, biochemical mechanisms, and off-target interactions, aiding in the efficient evaluation of compounds and their potential applications. Therefore, the extensive use of cell-based assays category in primary and secondary screening will contribute to the growth of the segment, thereby driving the growth of the overall high-throughput screening market during the forecast period.

North America is expected to dominate the overall High-Throughput Screening Market:

North America was estimated to account for the largest market share of the high-throughput screening market in 2024. This can be attributed to the rising number of patients suffering from chronic diseases such as cancer. The increasing government support and research funding and the presence of major players are some of the key driving factors contributing to the growth of the high-throughput screening market in North America.

One of the prominent factors supporting the growth of the North America high-throughput screening market is the extensive use of HTS assays in the identification and validation of tumor markers indicating cancer development. For instance, according to National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States. Additionally, as per the same source, prostate, lung, and colorectal cancer accounted for 43% of the cancer cases in men, and breast, lung, and colorectal making up to 50% of cancer cases in women. This indicates the huge need for early drug development for disease treatment, therefore leading to the growth of high-throughput screening market in the region.

As per the data published by to US Government Accountability Office in May 2023, The National Institutes of Health (NIH), an agency within the Department of Health and Human Services (HHS), stands as the primary public funder of biomedical research and development (R&D). Between fiscal years 2017 and 2021, NIH allocated USD 97 billion for basic research, USD 28 billion for clinical trials and associated endeavors, and USD 9 billion for the training of biomedical professionals, as part of its commitment to advancing biomedical R&D. Therefore, the increasing government support for R&D which requires high-throughput screening techniques for drug development is promoting the growth of the market in the region.

The presence of key players and the development of advanced technologies to enhance the drug discovery process is one of the key factors contributing to the growth of the market in the region. These players are leveraging innovative technologies to accelerate drug research and clinical trials. In February 2022, Thermo Fisher Scientific Inc., announced its partnership with Medidata. In this collaboration, Thermo Fisher's PPD clinical research business partnered with Medidata Acorn AI, the advanced analytics insights division of Medidata, to create PPD TrueCast. The comprehensive enterprise application merged vast patient recruitment and site performance data with predictive models and advanced analytics. Such development by key players is expected to foster the growth of the high-throughput screening market in North America.

High-Throughput Screening Market Key Players:

Some of the key market players operating in the high-throughput screening market include Agilent Technologies, Inc., Axxam S.p.A., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., PerkinElmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Promega Corporation, Aurora Biomed Inc., Illumina, Inc., Oxford Nanopore Technologies plc, Corning Incorporated, F. Hoffmann-La Roche Ltd, Sygnature Discovery, BPS Bioscience, Inc., Revvity, Charles River Laboratories, Hamilton Company, UPM Biomedicals, and others.

Recent Developmental Activities in the High-Throughput Screening Market:

  • In November 2023, Axxam S.p.A. and Momentum Biotechnologies joined forces to offer distinctive drug discovery solutions tailored for biotechnology and pharmaceutical clients. Under this partnership, Axxam's meticulously curated chemical diversity library, consisting of 325,000 compounds, was accessible for high-throughput screening utilizing Momentum's mass spectrometry-based functional and binding assay platforms.
  • In July 2023, Illumina Inc., a US-based biotechnology company announced the launch of DRAGEN(TM) software for the analysis of next-generation sequencing data has been unveiled. DRAGEN 4.2 builds upon its accuracy and renowned flexibility and scalability, empowering efficient workflows and the extraction of valuable insights from genomic data for the identification of genetic disease causes, drug discovery, and population genomics.
  • In January 2023, Charles River Laboratories, Inc. completed the acquisition of SAMDI Tech, Inc., a prominent provider of high-quality, label-free high-throughput screening (HTS) solutions utilized in drug discovery research. By acquiring SAMDI Tech's cutting-edge, high-throughput screening technology, Charles River Laboratories is bolstering its drug discovery capabilities. This move enhanced its distinct capacity to act as an integrated partner, offering comprehensive support for early-stage drug research and development initiatives.

Key Takeaways from the High-Throughput Screening Market Report Study

  • Market size analysis for current High-Throughput Screening Market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global High-Throughput Screening market.
  • Various opportunities available for the other competitors in the High-Throughput Screening Market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current High-Throughput Screening market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for High-Throughput Screening market growth in the coming future?

Target audience who can be benefited from this High-Throughput Screening Market Report Study

  • High-Throughput Screening product providers
  • Research organizations and consulting companies
  • High-Throughput Screening related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in High-Throughput Screening
  • Various end-users who want to know more about the High-Throughput Screening Market and the latest technological developments in the High-Throughput Screening Market.

Frequently Asked Questions for the High-Throughput Screening Market:

1. What are High-Throughput Screening?

  • High-throughput screening (HTS) is a technique employed in drug discovery and biomedical research to rapidly and efficiently evaluate a large number of chemical compounds or biological samples for specific biological activity. It enables researchers to screen thousands to millions of compounds in a short timeframe, aiding in the identification of potential drug candidates, understanding biological pathways, and discovering new therapeutic agents.

2. What is the market for High-Throughput Screening?

  • The high-throughput screening market is estimated to grow at a CAGR of 10.61% during the forecast period from 2025 to 2032.

3. What are the drivers for the global High-Throughput Screening market?

  • The global high-throughput screening market is expected to a rapid pace due to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product developments by key players. Increasing technological advancements in drug discovery and the growing demand of precision medicine are some of the key factors contributing to propel the market expansion. Additionally, the increasing funding to accelerate drug discovery is also a key factor responsible for contributing to the positive growth of the high-throughput screening market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global High-Throughput Screening market?)

  • Some of the key market players operating in the high-throughput screening market include Agilent Technologies, Inc., Axxam S.p.A., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., PerkinElmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Promega Corporation, Aurora Biomed Inc., Illumina, Inc., Oxford Nanopore Technologies plc, Corning Incorporated, F. Hoffmann-La Roche Ltd, Sygnature Discovery, BPS Bioscience, Inc., Revvity, Charles River Laboratories, Hamilton Company, UPM Biomedicals, and others.

5. Which region has the highest share in the global High-Throughput Screening market?

  • North America was estimated to account for the largest market share of the high-throughput screening market in 2024. This can be attributed to the rising number of patients suffering from chronic diseases such as cancer. The increasing government support and research funding and the presence of major players are some of the key driving factors contributing to the growth of the high-throughput screening market in North America.

Table of Contents

1. High-Throughput Screening Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. High-Throughput Screening Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. High-Throughput Screening Market Key Factors Analysis

  • 5.1. High-Throughput Screening Market Drivers
    • 5.1.1. The rising prevalence of chronic and infectious disease
    • 5.1.2. Growing research collaborations and product developments by key players
    • 5.1.3. Increasing technological advancements in drug discovery
    • 5.1.4. Increasing funding to accelerate drug
  • 5.2. High-Throughput Screening Market Restraints and Challenges
    • 5.2.1. High cost associated with instrumentation and drug discovery process
    • 5.2.2. Complexities in the assay development process
  • 5.3. High-Throughput Screening Market Opportunity
    • 5.3.1. Integration of AI and machine learning in drug discovery
    • 5.3.2. Integration of data analytics

6. High-Throughput Screening Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. High-Throughput Screening Market Assessment

  • 7.1. By Product
    • 7.1.1. Instruments
    • 7.1.2. Reagents and Kits
    • 7.1.3. Software
  • 7.2. By Technology
    • 7.2.1. Cell-Based Assays
    • 7.2.2. Ultra-High-Throughput Screening
    • 7.2.3. Lab-On-A-Chip Technology
    • 7.2.4. Label-Free High-Throughput Screening
    • 7.2.5. Next-Generation Sequencing (NGS)
  • 7.3. By Application
    • 7.3.1. In Vitro ADME Analysis
    • 7.3.2. Drug Discovery & Development
    • 7.3.3. Therapeutic Drug Monitoring
    • 7.3.4. Lead Optimization
    • 7.3.5. Others
  • 7.4. By End-User
    • 7.4.1. Pharmaceutical And Biotechnology Companies
    • 7.4.2. Contract Research Organizations
    • 7.4.3. Academic and Government Institutes
    • 7.4.4. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.3.3. India High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa High-Throughput Screening Market Size in USD million (2022-2032)
      • 7.5.4.3. South America High-Throughput Screening Market Size In USD Million (2022-2032)

8. High-Throughput Screening Market Company and Product Profiles

  • 8.1. Agilent Technologies, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Axxam S.p.A.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Danaher Corporation
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Bio-Rad Laboratories, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Merck & Co., Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. PerkinElmer Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Tecan Trading AG
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Thermo Fisher Scientific Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Promega Corporation
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Aurora Biomed Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Illumina, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Oxford Nanopore Technologies plc
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Corning Incorporated
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. F. Hoffmann-La Roche Ltd
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Sygnature Discovery
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. BPS Bioscience, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Revvity
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Charles River Laboratories
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Hamilton Company
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. UPM Biomedicals
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: High-Throughput Screening Market in Global (2022-2032)
  • Table 3: High-Throughput Screening Market in Global by Product (2022-2032)
  • Table 4: High-Throughput Screening Market in Global by Technology (2022-2032)
  • Table 5: High-Throughput Screening Market in Global by Application (2022-2032)
  • Table 6: High-Throughput Screening Market in Global by End-User (2022-2032)
  • Table 7: High-Throughput Screening Market in Global by Geography (2022-2032)
  • Table 8: High-Throughput Screening Market in North America (2022-2032)
  • Table 9: High-Throughput Screening Market in the US (2022-2032)
  • Table 10: High-Throughput Screening Market in Canada (2022-2032)
  • Table 11: High-Throughput Screening Market in Mexico (2022-2032)
  • Table 12: High-Throughput Screening Market in Europe (2022-2032)
  • Table 13: High-Throughput Screening Market in France (2022-2032)
  • Table 14: High-Throughput Screening Market in Germany (2022-2032)
  • Table 15: High-Throughput Screening Market in the United Kingdom (2022-2032)
  • Table 16: High-Throughput Screening Market in Italy (2022-2032)
  • Table 17: High-Throughput Screening Market in Spain (2022-2032)
  • Table 18: High-Throughput Screening Market in Rest of Europe (2022-2032)
  • Table 19: High-Throughput Screening Market in Asia-Pacific (2022-2032)
  • Table 20: High-Throughput Screening Market in China (2022-2032)
  • Table 21: High-Throughput Screening Market in Japan (2022-2032)
  • Table 22: High-Throughput Screening Market in India (2022-2032)
  • Table 23: High-Throughput Screening Market in Australia (2022-2032)
  • Table 24: High-Throughput Screening Market in South Korea (2022-2032)
  • Table 25: High-Throughput Screening Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: High-Throughput Screening Market in Rest of the World (2022-2032)
  • Table 27: High-Throughput Screening Market in the Middle East (2022-2032)
  • Table 28: High-Throughput Screening Market in Africa (2022-2032)
  • Table 29: High-Throughput Screening Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: High-Throughput Screening Market in Global (2022-2032)
  • Figure 3: High-Throughput Screening Market in Global by Product (2022-2032)
  • Figure 4: High-Throughput Screening Market in Global by Technology (2022-2032)
  • Figure 5: High-Throughput Screening Market in Global by Application (2022-2032)
  • Figure 6: High-Throughput Screening Market in Global by End-User (2022-2032)
  • Figure 7: High-Throughput Screening Market in Global by Geography (2022-2032)
  • Figure 8: High-Throughput Screening Market in North America (2022-2032)
  • Figure 9: High-Throughput Screening Market in the US (2022-2032)
  • Figure 10: High-Throughput Screening Market in Canada (2022-2032)
  • Figure 11: High-Throughput Screening Market in Mexico (2022-2032)
  • Figure 12: High-Throughput Screening Market in Europe (2022-2032)
  • Figure 13: High-Throughput Screening Market in France (2022-2032)
  • Figure 14: High-Throughput Screening Market in Germany (2022-2032)
  • Figure 15: High-Throughput Screening Market in the United Kingdom (2022-2032)
  • Figure 16: High-Throughput Screening Market in Italy (2022-2032)
  • Figure 17: High-Throughput Screening Market in Spain (2022-2032)
  • Figure 18: High-Throughput Screening Market in Rest of Europe (2022-2032)
  • Figure 19: High-Throughput Screening Market in Asia-Pacific (2022-2032)
  • Figure 20: High-Throughput Screening Market in China (2022-2032)
  • Figure 21: High-Throughput Screening Market in Japan (2022-2032)
  • Figure 22: High-Throughput Screening Market in India (2022-2032)
  • Figure 23: High-Throughput Screening Market in Australia (2022-2032)
  • Figure 24: High-Throughput Screening Market in South Korea (2022-2032)
  • Figure 25: High-Throughput Screening Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: High-Throughput Screening Market in Rest of the World (2022-2032)
  • Figure 27: High-Throughput Screening Market in the Middle East (2022-2032)
  • Figure 28: High-Throughput Screening Market in Africa (2022-2032)
  • Figure 29: High-Throughput Screening Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis